Literature DB >> 2977757

Isolation and structure determination of the main related substances of teicoplanin, a glycopeptide antibiotic.

A Cometti1, G G Gallo, J Kettenring, G B Panzone, G Tuan, L F Zerilli.   

Abstract

Teicoplanin is a complex formed by five closely related glycopeptides and by a small amount of a hydrolysis product. Minor quantities of related substances are also present. Two of them (named RS-1 and RS-2) were isolated and purified starting from the tailing fractions of a teicoplanin batch. Preparative reversed-phase liquid chromatography on large low-pressure and medium high-pressure scales, concentration, desalting, and freeze-drying steps were applied. 300 mg of RS-1 and 900 mg of RS-2 were obtained in a purity grade (about 90%) sufficient for structural investigation. Starting from considerations on the HPLC retentivity and on biosynthesis, the structures were assigned on the basis of 1H-N.M.R. spectra and homonuclear CO-SY 2D experiments, FAB-MS spectrometry, and GC-MS of the esters of the fatty acids obtained by hydrolysis. RS-1 and RS-2 are teicoplanins having 10-methyl-undecanoic acid and n-dodecanoic acid, respectively as fatty acid chains. No major difference in the in vitro activity of these teicoplanins emerged in comparison with teicoplanin complex.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2977757

Source DB:  PubMed          Journal:  Farmaco Sci        ISSN: 0430-0920


  3 in total

1.  Teicoplanin metabolism in rats.

Authors:  L F Zerilli; L Cavenaghi; A Bernareggi; A Assandri
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  Pharmacokinetics of individual components of teicoplanin in man.

Authors:  A Bernareggi; A Danese; A Cometti; G Buniva; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

3.  Teicoplanin metabolism in humans.

Authors:  A Bernareggi; A Borghi; M Borgonovi; L Cavenaghi; P Ferrari; K Vékey; M Zanol; L F Zerilli
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.